Genetic safety screening is paramount in the development of pharmaceuticals. Chemicals that develop mutations in the genetic material at preclinical models can be withdrawn to proceed further or give chance to put efforts to make safe dose. The Bacterial Reverse Mutation Test usually referred as Ames test is used world-wide as an initial screen to determine the mutagenic potential of new chemicals and drugs. The test is also used for submission of data to regulatory agencies for registration or acceptance of many chemicals, including drugs and biocides which are the cause of many human genetic diseases.
Ames test is a rapid and reliable bacterial assay used to evaluate a chemical's potential genotoxicity by measuring its ability to induce reverse mutations at selected loci of modified Salmonella and E.coli bacterial strains. These strains have various mutations and not capable to synthesis of an essential amino acid, either histidine (Salmonella) or tryptophan (E. coli), so they can only grow in the culture medium that is supplemented with that amino acid. Once the bacteria are exposed to a mutagen, mutation(s) occur that could restore/reverse the ability of the bacteria to synthesize the amino acid and to continue growth even after depletion of traces of provided amino acid in the agar. Relevant mutations involve substitution of individual base pairs or frameshift mutations caused by addition or deletion of a stretch of DNA.
The Ames test can be carried out in the presence and absence of a metabolizing system (e.g., Aroclor 1254-induced rat liver S9 fraction) to identify potential mutagenicity by the parent compound and/or its metabolites.
For repeated and multiple screenings, we presenting Mini Ames Test by using TA98/TA100/E.coli wp2 strains; Non-GLP screening assay to evaluate the multiple compounds in each step especially where test item accessible at very less quantity.
We make the screening much more convenient by adding the one more high-throughput fluctuation assay. The extra added advantage in this service is which requires a very small amount of compound i.e. less than 50 mg. This is a 384-well plate method where Salmonella strains, TA98, TA100, TA1535 and TA1537 will be tested by exposing the test item in the exposure liquid purple colour media and mutations indicated as yellow colour colonies after incubation.
Aurigene Pharmaceutical Services is
that provides contract research and manufacturing services
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.